Loading...

APC/Cyanine7 anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK15_APCCyanine7_CD4_Antibody_020119
C57BL/6 mouse splenocytes were stained with CD3 FITC and CD4 (clone GK1.5) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right).
  • GK15_APCCyanine7_CD4_Antibody_020119
    C57BL/6 mouse splenocytes were stained with CD3 FITC and CD4 (clone GK1.5) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Save
100413 25 µg ¥15,490
100414 100 µg ¥38,270
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Gu J, et al. 2023. J Cell Biochem. 124:557. PubMed
  2. Agrafiotis A, et al. 2023. iScience. 26:106055. PubMed
  3. Latour YL, et al. 2023. Gut Microbes. 15:2192623. PubMed
  4. Ludwig J, et al. 2023. NPJ Vaccines. 8:52. PubMed
  5. Sun R, et al. 2023. PLoS One. 18:e0282722. PubMed
  6. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  7. Vasanthakumar A, et al. 2020. Nature. 579:581. PubMed
  8. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
  9. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  10. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  11. Vick SC, et al. 2021. J Immunol. 207:2598. PubMed
  12. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  13. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  14. Campisi L, et al. 2022. Nature. 606:945. PubMed
  15. Silva Pereira S, et al. 2022. Elife. 11: . PubMed
  16. Molina MS, et al. 2022. PLoS One. 17:e0273075. PubMed
  17. Xu Y, et al. 2023. EMBO Rep. 24:e55503. PubMed
  18. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  19. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  20. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  21. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  22. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  23. Li H, et al. 2022. Cell Rep Med. 3:100554. PubMed
  24. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  25. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  26. Boyd DF, et al. 2020. Nature. 587:466. PubMed
  27. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  28. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  29. Pandey S, et al. 2020. Cell Syst. 11:495. PubMed
  30. Chen J, et al. 2021. Sci Adv. 7:. PubMed
  31. Dong L, et al. 2021. Cancer Cell. . PubMed
  32. Shao B, et al. 2018. Mol Med Rep. 18:920. PubMed
  33. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  34. Aldon Y, et al. 2020. J Immunol. 204:903. PubMed
  35. Andreas N, et al. 2021. Arthritis Res Ther. 23:222. PubMed
  36. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  37. Saito S, et al. 2020. Nutrients. 12:. PubMed
  38. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  39. Inoue D, et al. 2021. Nat Genet. 53:707. PubMed
  40. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  41. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  42. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  43. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
  44. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  45. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  46. Markov SD, et al. 2021. Mol Cancer Ther. 20:2457. PubMed
  47. Ontiveros-Padilla L, et al. 2021. Microorganisms. 9:. PubMed
  48. Ciarlo E, et al. 2016. Sci Rep. 6:37944. PubMed
  49. Yu X, et al. 2022. J Extracell Vesicles. 11:e12185. PubMed
  50. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  51. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  52. Mizraji* G, et al. 2013. J Vis Exp. 77: 50388. PubMed
  53. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  54. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
  55. Levescot A, et al. 2021. J Clin Invest. 131:. PubMed
  56. Levi J, et al. 2020. J Nucl Med. . PubMed
  57. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  58. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  59. Chun E, et al. 2020. Immunity. 51(5):871-884.e6.. PubMed
  60. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  61. Kleppe M et al. 2018. Cancer cell. 33(1):29-43 . PubMed
  62. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  63. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  64. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  65. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  66. Wennerberg E, et al. 2022. Sci Transl Med. 14:eabe8195. PubMed
  67. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  68. Mara AB, et al. 2022. NPJ Vaccines. 7:86. PubMed
  69. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  70. Zhang L, et al. 2021. Clin Transl Med. 11:e464. PubMed
  71. Gary E, et al. 2020. Vaccine. 3821:38. PubMed
  72. Zhang C, et al. 2020. Cell Rep. 32:108206. PubMed
  73. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
  74. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  75. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  76. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  77. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  78. Kräutler NJ, et al. 2020. Cell Reports. 30(4):997-1012.e6.. PubMed
  79. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  80. Yang S, et al. 2022. J Exp Med. 219:. PubMed
  81. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  82. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  83. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  84. Brown SM et al. 2017. Endocrinology. 158(10):3592-3604 . PubMed
  85. Sydney Lavoie et al. 2019. eLife. 8 pii: e39982. PubMed
  86. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  87. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  88. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  89. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  90. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  91. Merlo LM, et al. 2020. Clin Pathol. 13:2632010X20951812. PubMed
  92. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  93. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  94. Dong X, et al. 2022. Front Immunol. 13:896472. PubMed
  95. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  96. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  97. Yeung F, et al. 2020. Cell Host & Microbe. 27(5):809-822. PubMed
  98. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  99. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  100. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  101. Wang X, et al. 2021. Cell. 184:5357. PubMed
  102. Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed
  103. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  104. McNamee E, et al. 2013. Gut. 62:53. PubMed
  105. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  106. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  107. Jeon Y, et al. 2015. PLoS One. 10: e0139845. PubMed
  108. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  109. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  110. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  111. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  112. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  113. Chen B, et al. 2021. Cell. 184:6262. PubMed
  114. Wang X, et al. 2022. Elife. 11:. PubMed
  115. Ma C, et al. 2021. J Exp Med. :218. PubMed
  116. Wang M, et al. 2021. iScience. 24(7):102766. PubMed
  117. Sheng J, et al. 2021. eLife. 10:00. PubMed
  118. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  119. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  120. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  121. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  122. Liu A, et al. 2022. Front Cell Infect Microbiol. 12:960208. PubMed
  123. Sen D, et al. 2016. PLoS One. 11:e0165064. PubMed
  124. Young JS, et al. 2018. Front Immunol. 9:1385. PubMed
  125. Li A, et al. 2018. Cancer Lett. 431:54. PubMed
  126. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  127. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  128. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  129. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  130. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  131. Ma C, et al. 2020. Sci Adv. 6:eaaz6717. PubMed
  132. Wolf Y, et al. 2019. Cell. 179:219. PubMed
  133. Ershaid N, et al. 2019. Nat Commun. 10:4375. PubMed
  134. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
RRID
AB_312698 (BioLegend Cat. No. 100413)
AB_312698 (BioLegend Cat. No. 100414)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV395™ anti-mouse CD4 GK1.5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
Go To Top Version: 2    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account